Has Nirav Mistry, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,563 in general payments to Nirav Mistry, MD across 137 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nirav Mistry, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nirav Mistry, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nirav Mistry, MD

Critical Care Medicine · Livingston, NJNPI 1912162066

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $948 and has fallen 76.4% since, to $223 in 2025.

$3,563in general payments, 2019–2025

Across 137 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$589
Esperion Therapeutics, Inc.$449
AbbVie$367
La Jolla Pharmaceutical Company$342
Gilead$251
CSL Behring$177
plus $1K from 24 others

What the payments were for

Food & beverage$3,563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	18	$589
Esperion Therapeutics, Inc.	4	$449
AbbVie(2 entities)	23	$367
La Jolla Pharmaceutical Company	5	$342
Gilead	19	$251
CSL Behring	12	$177
Edwards Lifesciences	1	$162
GSK	9	$152
Ceribell, Inc.	1	$139
Haemonetics Corporation	1	$121
Sanofi	2	$120
Chiesi USA, Inc.	7	$96
Actelion Pharmaceuticals US, Inc.	2	$61
Portola Pharmaceuticals, LLC	4	$55
Merck	4	$53
Mylan Specialty L.p.	3	$53
United Therapeutics Corporation	3	$52
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$44
Mindray DS USA, Inc.	1	$44
Boston Scientific	2	$37
Johnson & Johnson	2	$35
Mallinckrodt Hospital Products Inc.	2	$27
Pulmonx Corporation	1	$26
Melinta Therapeutics, LLC	2	$26
Medline Industries LP	1	$15
UCB, Inc.	1	$15
Philips North America LLC	1	$15
Boehringer Ingelheim	1	$14
Shionogi Inc	1	$13
E.r. Squibb & Sons, L.L.C.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,563 in reported general payments places this provider in the 80th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024

$53,684

Medicare patients

105

Services billed

285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Livingston

Fariborz RezaiLivingston$2.3M
Kristin FlessLivingston$10K
Bilal KhanLivingston$4K
Eric TellerHackensack$217K
R Phillip DellingerCamden$74K
Raghad SaidHackensack$48K
Neha VagadiaMarlton$31K
Mark RamzyWest Orange$31K
Shawana HussainCamden$19K
Theodore PlushCamden$18K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →